Tuesday, 17 November 2026 Every SEC filing alert, by company
ALFA USA Filings Every alert, straight from SEC EDGAR
News
Earnings Call

Becton, Dickinson and Earnings Call: Key Takeaways

BDX completed its transformation to a pure-play MedTech company, delivering 5.6% revenue growth in Q4 while navigating Alaris headwinds and significant tariff impacts through operational excellence and biologic drug delivery momentum.

Full earnings call on the Alfa Finder USA YouTube channel · Open on YouTube ↗
Highlights
Revenue GrowthMedical Essentials 5.9%, Connected Care 2.1%, Biopharma 7%, Interventional 7.6%.
Mgmt ConfidenceHigh confidence in 'New BD' strategy and sustainable mid-single digit growth.
Demand VisibilityStrong utilization in US; 100% attachment rate for new AI platform.
Order BookStrong PICS Pro order momentum; won all six central fill opportunities.
Margin TrendsFY27 operating margins expected flat; 180bps gross margin expansion in Q4.
Op. LeverageBD Excellence driving 8% gross productivity in plants; $200M cost-out program.
Pricing PowerAbility to increase prices used to mitigate inflationary headwinds.
Vol vs PriceGrowth driven by share gains, utilization, and favorable product mix.
Segment GrowthAdvanced Patient Monitoring and PureWick delivered double-digit growth.
New ClientsLandmark US government partnership; 100 biologic deals signed including Brazil pen.
Capex & Debt$19B US investment commitment; $2.4B debt paid; 2.7x net leverage.
RegulatorySection 232 tariff relief pending; FDA approval for Liberty Tip Stent.
CommentaryShift to high-growth platforms creates a margin-accretive flywheel effect.
New LaunchesBD VMAX, Liberty Tip Stent, Phasix ST Parastomal, Ancata AI platform.

Growth

Q4 revenue grew 5.6% to $5.3B; Medical Essentials up 5.9%, Interventional up 7.6%.

Outlook

FY27 revenue growth guided low-single digits; adjusted EPS target $13.10 to $13.30.

Risks

Alaris capital comparison creates 200bps headwind for FY27; Q1 growth expected at low end.

Source

The company's earnings call, NYSE: BDX, and its 8-K filed with the SEC. Summary written with AI assistance from the call.

Read the 8-K ↗

Becton Dickinson & Co: key numbers

Share price
$216.47Close, Nov 16
Market cap
$59B
Shares outstanding
272.39MLatest SEC cover page
Sector
Industrial Applications and Services
Industry
Surgical & Medical Instruments & ApparatusSIC 3841

Today's reference numbers, updated daily. Not a valuation or a recommendation.

More from Becton Dickinson & Co

All →
5:45 PM ET Form 4
Insider Selling

Becton Dickinson & Chairman, CEO and President Thomas E. Polen Jr. Sells $629K of Stock

Thomas E. Polen Jr., Chairman, CEO and President, sold 2,993 shares of Becton Dickinson & Co at $210.00 a share, worth $629K in total on Nov 5, 2026. Shares held after the trade: 110,163 (-2.6%).

Value
$629K
Shares
2,993
Price
$210.00
Role
Chairman, CEO and President
Holding change
-2.6%
Trade date
Nov 5, 2026
6:32 AM ET 8-K
Financial Results

Becton Dickinson & Financial Results

Becton, Dickinson and Company (BD) reported Q4 fiscal 2026 revenue of $5.3 billion, a 5.4% increase, and full-year revenue of $19.5 billion. The company highlighted the completion of its transformation into a more focused MedTech company following the separation of its Life Sciences business and issued guidance for fiscal 2027.

“We delivered a strong fourth quarter, with 5.6% revenue growth and broad-based performance led by our key growth platforms. Fiscal 2026 was a defining year as we completed BD's transformation to a more focused MedTech company with separation of our Life Sciences business. We strengthened our core growth and expanded BD Excellence to elevate our commercial capabilities, accelerate innovation and drive greater productivity. We enter fiscal 2027 from a position of strength, with a portfolio built for durable performance and confidence in the long-term growth, earnings and cash-flow potential of New BD.”

Tom Polen, chairman, CEO and president of BD
2:27 PM ET Form 4
Insider Selling

Becton Dickinson & EVP, Chief Revenue Officer Michael Feld Sells $15.1K of Stock

Michael Feld, EVP, Chief Revenue Officer, sold 76 shares of Becton Dickinson & Co at $198.13 a share, worth $15.1K in total on Oct 26, 2026. Shares held after the trade: 19,568 (-0.4%).

Value
$15.1K
Shares
76
Price
$198.13
Role
EVP, Chief Revenue Officer
Holding change
-0.4%
Trade date
Oct 26, 2026
2:20 AM ET Form 4
Insider Selling

Becton Dickinson & EVP, Chief Revenue Officer Michael Feld Sells $14K of Stock

Michael Feld, EVP, Chief Revenue Officer, sold 76 shares of Becton Dickinson & Co at $183.70 a share, worth $14K in total on Sep 28, 2026. Shares held after the trade: 19,644 (-0.4%).

Value
$14K
Shares
76
Price
$183.70
Role
EVP, Chief Revenue Officer
Holding change
-0.4%
Trade date
Sep 28, 2026

Get Alerts

Get ALFA Finder alerts first

Real-time SEC filing alerts for US stocks are launching soon. Leave your details and we'll tell you the moment they go live.